Sign in
Aspernolide F, as a new cardioprotective butyrolactone against doxorubicin-induced cardiotoxicity
Journal article   Peer reviewed

Aspernolide F, as a new cardioprotective butyrolactone against doxorubicin-induced cardiotoxicity

Dina S El-Agamy, Sabrin R M Ibrahim, Nishat Ahmed, Saad Khoshhal, Hany M Abo-Haded, Mohamed A Elkablawy, Naif Aljuhani and Gamal A Mohamed
International immunopharmacology, Vol.72, pp.429-436
07/2019
PMID: 31030099

Abstract

Animals Antibiotics, Antineoplastic Antioxidants - isolation & purification Antioxidants - pharmacology Antioxidants - therapeutic use Aspergillus Cardiotonic Agents - isolation & purification Cardiotonic Agents - pharmacology Cardiotonic Agents - therapeutic use Cardiotoxicity - drug therapy Cardiotoxicity - metabolism Doxorubicin Interleukin-6 - metabolism Male Myocardium - metabolism Myocardium - pathology NF-kappa B - metabolism Nitric Oxide - metabolism Oxidative Stress - drug effects Rats, Wistar Tumor Necrosis Factor-alpha - metabolism

Metrics

1 Record Views

Details